Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Lidan Hao
Advertisement
Articles by Lidan Hao
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
Navigating New Horizons in Neuroendocrine Prostate Cancer
5